Valuation: SELLAS Life Sciences Group, Inc.

Market Cap 2.51B 2.19B 2.02B 1.87B 3.55B 239B 3.61B 24.19B 9.5B 118B 9.42B 9.22B 405B P/E 2026 *
-60.8x
P/E 2027 * -102x
Enterprise Value 2.51B 2.19B 2.02B 1.87B 3.55B 239B 3.61B 24.19B 9.5B 118B 9.42B 9.22B 405B EV / Sales 2026 *
-
EV / Sales 2027 * 47.3x
Free-Float
99.05%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: SELLAS Life Sciences Group, Inc.

1 day-5.55%
1 week-14.82%
Current month-13.55%
1 month+64.65%
3 months+168.07%
6 months+268.79%
Current year+238.46%
1 week 12
Extreme 12
15.57
1 month 7.43
Extreme 7.4252
15.88
Current year 3.23
Extreme 3.23
15.88
1 year 1.39
Extreme 1.39
15.88
3 years 0.5
Extreme 0.4986
15.88
5 years 0.5
Extreme 0.4986
15.88
10 years 0.5
Extreme 0.4986
554.5
Manager TitleAgeSince
Chief Executive Officer 50 28/12/2017
Director of Finance/CFO 41 29/12/2017
Compliance Officer - -
Director TitleAgeSince
Director/Board Member 50 28/12/2017
Chairman 66 31/05/2024
Director/Board Member 69 28/12/2017
Date Insider Type Main position Quantity % Market Cap.
06-15Free

Founder

1,065,000 0.5725%
01-06Free

Director

50,000 0.0351%
01-06Free

Director

50,000 0.0351%
Change 5-day change 1-year change 3-year change Capi.($)
-5.55%-14.82%+593.48%+641.86% 2.51B
+1.84%-0.66%+59.82%+92.96% 54.88B
-4.14%-8.06%+58.96%+118.67% 54.63B
-2.24%+3.59%+17.75%+477.47% 25.06B
-1.60%-6.21%-18.96%-15.21% 23.14B
+2.43%+1.06%+42.44%-1.27% 19.87B
-3.19%0.00%+35.60%-26.98% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
+8.74%+3.51%+51.91%+726.40% 15.75B
-1.05%+1.16%+25.95%+194.27% 14.2B
Average -1.16%-1.73%+106.21%+256.53% 24.41B
Weighted average by Cap. -0.94%-1.59%+56.84%+181.91%

Financials

2026 *2027 *
Net sales - 53.09M 46.44M 42.84M 39.56M 75.07M 5.06B 76.33M 512M 201M 2.49B 199M 195M 8.58B
Net income -37.97M -33.22M -30.64M -28.3M -53.69M -3.62B -54.6M -366M -144M -1.78B -143M -139M -6.13B -26.29M -22.99M -21.21M -19.59M -37.17M -2.51B -37.79M -253M -99.51M -1.24B -98.7M -96.55M -4.25B
Net Debt - -
Logo SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
Employees
13
Date Price Change Volume
10/07/26 US$12.76 -5.55% 6,405,799
09/07/26 US$13.51 -1.82% 7,060,007
08/07/26 US$13.76 +1.93% 15,193,987
07/07/26 US$13.50 -3.16% 8,164,662
06/07/26 US$13.94 -6.94% 9,746,734
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
12.76USD
Average target price
27.50USD
Spread / Average Target
+115.52%

Quarterly revenue - Rate of surprise